Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Rosaria Di Lorenzo, Paola Ferri, Michela Cameli, Sergio Rovesti & Chiara Piemonte. (2019) Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatric Disease and Treatment 15, pages 183-198.
Read now
Read now
Nesrin Dilbaz. (2015) New Targets for the Management of Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25:4, pages 407-428.
Read now
Read now
Peter M Haddad, Cecilia Brain & Jan Scott. (2014) Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures 5, pages 43-62.
Read now
Read now
Richard Williams, Ranjith Chandrasena, Linda Beauclair, Doanh Luong & Annette Lam. (2014) Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada. Neuropsychiatric Disease and Treatment 10, pages 417-425.
Read now
Read now
Andreas Schreiner, Anders Svensson, Robert Wapenaar, Pierre Cherubin, Patricia Princet, Larisa Serazetdinova & Mathias Zink. (2014) Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). The World Journal of Biological Psychiatry 15:7, pages 534-545.
Read now
Read now
Gabriel Kaplan, Julio Casoy & Jacqueline Zummo. (2013) Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Preference and Adherence 7, pages 1171-1180.
Read now
Read now
Thomas R. Einarson & Michiel E. H. Hemels. (2013) Validation of an economic model of paliperidone palmitate for chronic schizophrenia. Journal of Medical Economics 16:11, pages 1267-1274.
Read now
Read now
Luis San, Miquel Bernardo, Agustín Gómez & Mario Peña. (2013) Factors associated with relapse in patients with schizophrenia. International Journal of Psychiatry in Clinical Practice 17:1, pages 2-9.
Read now
Read now
Luis San, Miquel Bernardo, Agustín Gómez, Pedro Martínez, Beatriz González & Mario Peña. (2013) Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. Nordic Journal of Psychiatry 67:1, pages 22-29.
Read now
Read now
Angelika Mehnert, Deborah Nicholl, Hanna Pudas, Monique Martin & Alistair McGuire. (2012) Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. Journal of Medical Economics 15:5, pages 844-861.
Read now
Read now
Pierre Chue & James Chue. (2012) The cost–effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Expert Review of Pharmacoeconomics & Outcomes Research 12:3, pages 259-269.
Read now
Read now
L Annemans, I Eijgelshoven, A Smet, A Jacobs & G Bergman. (2012) THE IMPACT OF TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION ON THE BELGIAN HEALTHCARE SYSTEM: RESULTS FROM A BUDGET IMPACT MODEL. Acta Clinica Belgica 67:2, pages 108-119.
Read now
Read now
Miguel Bernardo, Luis San, José M Olivares, Tatiana Dilla, Pepa Polavieja, Inmaculada Gilaberte, María Álvarez & Antonio Ciudad. (2011) Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. Patient Preference and Adherence 5, pages 601-610.
Read now
Read now
Rogelio Apiquian, Rodrigo Córdoba & Mario Louzã. (2011) Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatric Disease and Treatment 7, pages 19-26.
Read now
Read now
Vishal Madaan, Durga P Bestha, Venkata Kolli, Saurabh Jauhari & Roger C Burket. (2011) Clinical utility of the risperidone formulations in the management of schizophrenia. Neuropsychiatric Disease and Treatment 7, pages 611-620.
Read now
Read now
Articles from other publishers (35)
Alysia M. Berglund, Ian M. Raugh, Kelsey I. Macdonald, Sydney H. James, Lisa A. Bartolomeo, Anna R. Knippenberg & Gregory P. Strauss. (2023) The effects of the COVID-19 pandemic on hallucinations and delusions in youth at clinical high-risk for psychosis and outpatients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience.
Crossref
Crossref
Andrea Aguglia, Laura Fusar-Poli, Antimo Natale, Andrea Amerio, Irene Espa, Veronica Villa, Giovanni Martinotti, Giuseppe Carrà, Francesco Bartoli, Armando D’Agostino, Gianluca Serafini, Mario Amore, Eugenio Aguglia, Giovanni Ostuzzi & Corrado Barbui. (2022) Factors Associated with Medication Adherence to Long-Acting
Injectable Antipsychotics: Results from the STAR Network Depot
Study. Pharmacopsychiatry 55:06, pages 281-289.
Crossref
Crossref
Sun Lee & Shaina Schwartz. (2021) Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: A systematic review and meta-analysis of cohort studies. Psychiatry Research 306, pages 114277.
Crossref
Crossref
Sandeep Grover, Swapnajeet Sahoo & Aseem Mehra. (2019) Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics. Journal of Clinical Psychopharmacology 39:6, pages 611-619.
Crossref
Crossref
Philip D. Harvey, Martin T. Strassnig & Juliet Silberstein. (2019) Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment. Journal of Experimental Psychopathology 10:3, pages 204380871986569.
Crossref
Crossref
Isabella Pacchiarotti, Jari Tiihonen, Georgios D. Kotzalidis, Norma Verdolini, Andrea Murru, José Manuel Goikolea, Marc Valentí, Alberto Aedo & Eduard Vieta. (2019) Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. European Neuropsychopharmacology 29:4, pages 457-470.
Crossref
Crossref
Kruti Joshi, Lian Mao, David M. Biondi & Robert Millet. (2018) The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia. BMC Psychiatry 18:1.
Crossref
Crossref
Juha Käkelä, Riikka Marttila, Emmi Keskinen, Juha Veijola, Matti Isohanni, Heli Koivumaa-Honkanen, Marianne Haapea, Erika Jääskeläinen & Jouko Miettunen. (2017) Association between family history of psychiatric disorders and long-term outcome in schizophrenia – The Northern Finland Birth Cohort 1966 study. Psychiatry Research 249, pages 16-22.
Crossref
Crossref
Ha Hyun BaeEui Hyeon NAHai Joo YoonEun Kyung ParkJong-Il Lee. (2017) A Study on Discontinuation Rate on Maintenance Treatment of Antipsychotic Agents in Schizophrenic Patients. Korean Journal of Schizophrenia Research 20:2, pages 69.
Crossref
Crossref
Hidenobu Suzuki, Hiroyuki Hibino & Yuichi Inoue. (2016) Changes in length of hospital stay before and after the administration of a long-acting injection in patients with schizophrenia: Mirror-image study. Psychiatry and Clinical Neurosciences 70:6, pages 255-255.
Crossref
Crossref
Hong Kyu IhmSang Hoon KimJung Ho KimKang Su HaHyun Park. (2016) Factors Related to Medication Adherence in Outpatients with Schizophrenia under More Than 5 Years of Treatment. Journal of Korean Neuropsychiatric Association 55:4, pages 397.
Crossref
Crossref
Robin Emsley, Koksal Alptekin, Jean-Michel Azorin, Fernando Cañas, Vincent Dubois, Philip Gorwood, Peter M. Haddad, Dieter Naber, José Manuel Olivares, Georgios Papageorgiou, Miguel Roca, Pierre Thomas, Ludger Hargarter & Andreas Schreiner. (2015) Nurses’ perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey. Therapeutic Advances in Psychopharmacology 5:6, pages 339-350.
Crossref
Crossref
Juan J. Fernández-Miranda, Victoria Caramés-García & Arantxa Sánchez-García. (2015) Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia. Journal of Clinical Psychopharmacology 35:6, pages 630-634.
Crossref
Crossref
Lan-Ting Lee, Kao Chin Chen, Wei Hung Chang, Po See Chen, I Hui Lee & Yen Kuang Yang. (2015) Holistic Consideration of Patients with Schizophrenia to Improve Medication Adherence and Outcomes. Clinical Psychopharmacology and Neuroscience 13:2, pages 138-143.
Crossref
Crossref
Henry A. Nasrallah, Philip D. Harvey, Daniel Casey, Csilla T. Csoboth, James I. Hudson, Laura Julian, Ellen Lentz, Keith H. Nuechterlein, Diana O. Perkins, Nirali Kotowsky, Tracey G. Skale, Lonnie R. Snowden, Rajiv Tandon, Cenk Tek, Dawn Velligan, Sophia Vinogradov & Cedric O’Gorman. (2015) The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization. Schizophrenia Research 166:1-3, pages 69-79.
Crossref
Crossref
David S. Hutchins, John E. Zeber, Craig S. Roberts, Allison F. Williams, Elizabeth Manias & Andrew M. Peterson. (2015) Initial Medication Adherence—Review and Recommendations for Good Practices in Outcomes Research: An ISPOR Medication Adherence and Persistence Special Interest Group Report. Value in Health 18:5, pages 690-699.
Crossref
Crossref
A. Ameller & P. Gorwood. (2015) Poids de la comorbidité addictive dans le risque d’observance partielle au traitement médicamenteux et de rechute dans la schizophrénie. L'Encéphale 41:2, pages 174-183.
Crossref
Crossref
Elaine H Morrato, Joe Parks, Elizabeth J Campagna, Erik Muser, Deborah SK Thomas, Hai Fang & Dilesh Doshi. (2015) Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. Journal of Comparative Effectiveness Research 4:2, pages 89-99.
Crossref
Crossref
Ryan Turncliff, Marjie Hard, Yangchun Du, Robert Risinger & Elliot W. Ehrich. (2014) Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophrenia Research 159:2-3, pages 404-410.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Vincent Dubois, Joseph Peuskens, Paul Geerts & Johan Detraux. (2014) Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schi. Early Intervention in Psychiatry 8:1, pages 39-49.
Crossref
Crossref
Luis Eduardo Jaramillo González, Carlos Gómez Restrepo, Jenny García Valencia, Ana María de la Hoz Bradford, Mauricio Ávila-Guerra & Adriana Bohórquez Peñaranda. (2014) Tratamiento con antipsicóticos de depósito del paciente adulto con diagnóstico de esquizofrenia. Revista Colombiana de Psiquiatría 44, pages 40-58.
Crossref
Crossref
Paul Geerts, Guadalupe Martinez & Andreas Schreiner. (2013) Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses. BMC Psychiatry 13:1.
Crossref
Crossref
Laura Lammers, Bree Zehm & Richard Williams. (2013) Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada. BMC Psychiatry 13:1.
Crossref
Crossref
Fernando Cañas, Koksal Alptekin, Jean Michel Azorin, Vincent Dubois, Robin Emsley, Antonio G. García, Philip Gorwood, Peter M. Haddad, Dieter Naber, José M. Olivares, Georgios Papageorgiou & Miquel Roca. (2013) Improving Treatment Adherence in Your Patients with Schizophrenia. Clinical Drug Investigation 33:2, pages 97-107.
Crossref
Crossref
Andreas Roussidis, Christina Kalkavoura, Dimos Dimelis, Afroditi Theodorou, Ina Ioannidou, Eleytherios Mellos, Triantafyllia Mylonaki, Areti Spyropoulou & Andreas Yfantis. (2013) Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study. Annals of General Psychiatry 12:1, pages 42.
Crossref
Crossref
Joseph Peuskens, Vibeke Porsdal, Jan Pecenak, Peter Handest, Yulia D'yachkova, Radim Brousil & Walter Deberdt. (2012) Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis. BMC Psychiatry 12:1.
Crossref
Crossref
E. Ceskova. (2012) Optimizing treatment with risperidone long‐acting injections. Acta Psychiatrica Scandinavica 126:6, pages 479-480.
Crossref
Crossref
Róbert Herold. (2012) The long-term treatment of schizophrenia. Orvosi Hetilap 153:26, pages 1007-1012.
Crossref
Crossref
Hui-Chih Chang, Chao-Hsiun Tang, Sheng-Tzu Huang, Paul McCrone & Kuan-Pin Su. (2012) A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: A one-year mirror-image study with national claim-based database in Taiwan. Journal of Psychiatric Research 46:6, pages 751-756.
Crossref
Crossref
Francisco Javier Acosta. (2012) Medication adherence in schizophrenia. World Journal of Psychiatry 2:5, pages 74.
Crossref
Crossref
Nicolas M Furiak, James C Gahn, Robert W Klein, Stephen B Camper & Kent H Summers. (2012) Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model. Annals of General Psychiatry 11:1, pages 29.
Crossref
Crossref
Wayne Macfadden, Cherilyn DeSouza, Concetta Crivera, Chris M Kozma, Riad D Dirani, Lian Mao & Stephen C Rodriguez. (2011) Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry 11:1.
Crossref
Crossref
A. J. M. Brnabic, K. Kelin, H. Ascher-Svanum, W. Montgomery, Z. Kadziola & J. Karagianis. (2011) Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study. International Journal of Clinical Practice 65:9, pages 945-953.
Crossref
Crossref
Leslie Citrome, Ari Jaffe & Jerome Levine. (2010) Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. Schizophrenia Research 119:1-3, pages 153-159.
Crossref
Crossref